- Home
- Publications
- Publication Search
- Publication Details
Title
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume 23, Issue 5, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-11
DOI
10.1007/s11883-021-00914-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model
- (2020) Eva Hurt-Camejo JOURNAL OF LIPID RESEARCH
- Evinacumab for Homozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes
- (2019) Eliza Christopoulou et al. DISEASE MARKERS
- Lipid-Lowering Agents
- (2019) Robert A. Hegele et al. CIRCULATION RESEARCH
- Therapeutic Antisense Oligonucleotides Are Coming of Age
- (2019) C. Frank Bennett Annual Review of Medicine
- Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
- (2019) Marja-Riitta Taskinen et al. Current Atherosclerosis Reports
- Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia
- (2019) Zahid Ahmad et al. CIRCULATION
- Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014
- (2019) Wenjun Fan et al. DIABETES CARE
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- (2019) Joseph L. Witztum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity
- (2019) Poulabi Banerjee et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks
- (2019) Elad Shemesh et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice
- (2019) Marianne G. Pouwer et al. JOURNAL OF LIPID RESEARCH
- Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities
- (2018) Kyriakos E. Kypreos et al. ANGIOLOGY
- Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol
- (2018) Yu-Xin Xu et al. ATHEROSCLEROSIS
- An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans
- (2018) Adil Mardinoglu et al. Cell Metabolism
- The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
- (2018) Angela Pirillo et al. Current Atherosclerosis Reports
- Novel Hypolipidaemic Drugs: Mechanisms Of Action And Main Metabolic Effects
- (2018) Theodosios D. Filippatos et al. Current Vascular Pharmacology
- Molecular actions of PPARα in lipid metabolism and inflammation
- (2018) Nadia Bougarne et al. ENDOCRINE REVIEWS
- Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials
- (2018) Amirhossein Sahebkar et al. Journal of Clinical Lipidology
- INHIBITION OF APOLIPOPROTEIN C-III WITH GALNAC CONJUGATED ANTISENSE DRUG POTENTLY LOWERS FASTING SERUM APOLIPOPROTEIN C-III AND TRIGLYCERIDE LEVELS IN HEALTHY VOLUNTEERS WITH ELEVATED TRIGLYCERIDES
- (2018) Veronica J. Alexander et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2ʹ-MOE-Modified Antisense Oligonucleotide
- (2018) Padmakumar Narayanan et al. TOXICOLOGICAL SCIENCES
- Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: the effect of weight reduction and realimentation
- (2018) Anna Cinkajzlová et al. Nutrition & Diabetes
- Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial
- (2018) Jeremy D Furtado et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials
- (2018) Amirhossein Sahebkar et al. ANNALS OF MEDICINE
- Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease
- (2018) Yating Wang et al. CLINICAL CARDIOLOGY
- Apolipoprotein CIII and diabetes. Is there a link?
- (2018) Eliza Christopoulou et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease
- (2018) Julia Dittrich et al. ATHEROSCLEROSIS
- Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions
- (2017) Saulo Mendoza et al. Journal of Clinical Lipidology
- Apolipoprotein C-III Inhibition With Volanesorsen in Patients With Hypertriglyceridemia (COMPASS): A Randomized, Double-Blind, Placebo-Controlled Trial
- (2017) Ioanna Gouni-Berthold et al. Journal of Clinical Lipidology
- The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
- (2017) D. Gaudet et al. Journal of Clinical Lipidology
- Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity
- (2017) Evangelia Zvintzou et al. JOURNAL OF LIPID RESEARCH
- Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III
- (2017) Raimund Pechlaner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- ANGPTL3 Deficiency and Protection Against Coronary Artery Disease
- (2017) Nathan O. Stitziel et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Angiopoietin-like 3 in lipoprotein metabolism
- (2017) Sander Kersten Nature Reviews Endocrinology
- ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
- (2017) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
- (2017) Mark J. Graham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
- (2017) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins
- (2017) Patrick R. Lawler et al. Journal of the American Heart Association
- Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol
- (2017) Patrick R. Lawler et al. Journal of the American Heart Association
- ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase
- (2017) Xun Chi et al. Molecular Metabolism
- Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
- (2016) Andres Digenio et al. DIABETES CARE
- Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
- (2016) Alan Chait et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
- (2016) Philip L.S.M. Gordts et al. JOURNAL OF CLINICAL INVESTIGATION
- Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
- (2016) Xiaohong Yang et al. JOURNAL OF LIPID RESEARCH
- The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism
- (2016) Mengdie Luo et al. Lipids in Health and Disease
- Lomitapide
- (2015) Sebastiaan C. Goulooze et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
- (2015) Yan Wang et al. JOURNAL OF LIPID RESEARCH
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apolipoprotein C-III
- (2015) Alison B. Kohan Current Opinion in Endocrinology Diabetes and Obesity
- Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation
- (2014) Anna Tikka et al. BIOSCIENCE REPORTS
- Rare Variant APOC3 R19X Is Associated With Cardio-Protective Profiles in a Diverse Population-Based Survey as Part of the Epidemiologic Architecture for Genes Linked to Environment Study
- (2014) D. C. Crawford et al. Circulation-Cardiovascular Genetics
- Effects of bariatric surgery on HDL structure and functionality: results from a prospective trial
- (2014) Evangelia Zvintzou et al. Journal of Clinical Lipidology
- HDL and cardiovascular disease
- (2014) Daniel J Rader et al. LANCET
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
- (2013) Mark J. Graham et al. CIRCULATION RESEARCH
- Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis
- (2013) Ilenia Minicocci et al. JOURNAL OF LIPID RESEARCH
- Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B
- (2012) Stanley T. Crooke et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in men
- (2012) N Faghihnia et al. EUROPEAN JOURNAL OF CLINICAL NUTRITION
- A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
- (2012) Anastazia A. Kei et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Qualitative characteristics of HDL in young patients of an acute myocardial infarction
- (2011) Anthula E. Kavo et al. ATHEROSCLEROSIS
- The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease
- (2011) Jamal S. Rana et al. Current Atherosclerosis Reports
- Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia
- (2010) Sandrine Caron et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients
- (2010) E. S. Nakou et al. LIPIDS
- Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation
- (2009) O. OLIVIERI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Mechanism of Action of Niacin
- (2008) Vaijinath S. Kamanna et al. AMERICAN JOURNAL OF CARDIOLOGY
- ABCA1 Promotes the de Novo Biogenesis of Apolipoprotein CIII-Containing HDL Particles in Vivo and Modulates the Severity of Apolipoprotein CIII-Induced Hypertriglyceridemia†
- (2008) Kyriakos E. Kypreos BIOCHEMISTRY
- Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
- (2008) Esther M. M. Ooi et al. CLINICAL SCIENCE
- Dose-Dependent Effect of Rosuvastatin on VLDL-Apolipoprotein C-III Kinetics in the Metabolic Syndrome
- (2008) E. M.M. Ooi et al. DIABETES CARE
- Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome
- (2008) Theodosios D. Filippatos et al. Journal of Clinical Lipidology
- A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
- (2008) T. I. Pollin et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started